Ex-GSK CEO to lead Alzheon's board; IBD startup raises $14.1M Series A;

@FierceBiotech: With Roche in the rearview mirror, Constellation Pharma grabs $55M round. Article | Follow @FierceBiotech

@JohnCFierce: Now we get to see if Merck KGaA can swing big and actually hit the ball. Article | Follow @JohnCFierce

> Former GlaxoSmithKline ($GSK) CEO Jean-Pierre Garnier has taken the chairman spot at Alzheon, a startup developing a treatment for Alzheimer's disease. More

> Biogen ($BIIB) is looking into leasing a 350,000-square-foot space in Cambridge, MA's biotech hotbed of Kendall Square, the Boston Business Journal reports. News

> Canadian biotech upstart Inception IBD closed a $14.1 million Series A round to support its work on treatments for inflammatory bowel disease. Versant Ventures led the round, joined by Fonds de solidarité FTQ and Inserm Transfert Initiative. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Chemotherapy cooling cap to reduce hair loss for breast cancer patients gets FDA nod. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Edwards grabs option to acquire transcather mitral valve replacement startup. Article | Follow @VarunSaxena2

@EmilyWFierce: Cornell scientists create first litter of puppies through in vitro fertilization. FierceAnimalHealth story | Follow @EmilyWFierce

> Edwards ($EW) bets on treating degenerative regurgitation via mitral repair with Harpoon investment. More

> Bloomberg: Embattled Theranos CEO continues to beat the 'transparency' drum. Story

> MicroTransponder reels in $5.5M for stroke neurostimulation device. Article

Pharma News

@FiercePharma: India's Dr. Reddy's responds to U.S. FDA warning letter. FiercePharmaAsia article | Follow @FiercePharma

@CarlyHFierce: I'm sorry, but you had 20 years to brainstorm on this, and you came up with "Dengvaxia?"  | Follow @CarlyHFierce

> FDA Commissioner to talk drug safety with top Chinese officials. More

> Sanofi ($SNY) gets first approval for long-anticipated vaccine against dengue fever. Story

> McCaskill raps 'Mr. Wu-Tang' Shkreli in Senate hearing over drug price hikes. Article

CRO News

> Icon ($ICLR) buys a trial site network with an eye on patient data. News

> WuXi ($WX) and PRA ($PRAH) break up their Chinese joint venture. More

> Charles River ($CRL) digs into Parkinson's R&D with Fox Foundation in tow. Story

> Quintiles ($Q) extends its R&D hand-holding service to biopharmas large and small. Report

> Restructured AMRI ($AMRI) cuts the ribbon on a drug discovery hub. Article

Pharma Manufacturing News

> Sucampo ($SCMP) finalizes $278M deal of R-Tech Ueno's manufacturing plant in Japan. News

> Axxess Pharma ($AXXE) has tapped SDC Nutrition for product manufacturing. Report

> FDA issues import alert on Pan Pharma, ramping up its pressure on the India drugmaker. Story

> Eli Lilly ($LLY) to manufacture human and animal drugs in separate facilities. Article

> Study: Shortfall of skilled inspectors in India hinders pharma industry. Item

Pharma Asia News

> WuXi and PRA Health amend ties in China. Item

> U.S. FDA files import alert on India's Pan Drugs. More

> China aims precision medicine plans at chronic diseases. Report

> Bangladesh again noted for dominant domestic drug manufacture. Story

> Takeda inks pact with Cour for celiac disease therapy via nanoparticles. Article

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.